Our technology is revolutionizing GPCR drug discovery
Unparalleled GPCR targeting
Our patent-protected platform excels in its ability to modulate specific GPCR forms, offering a competitive advantage particularly on receptors traditionally viewed as challenging.
Multiple modalities
Whether small molecules or biologics, our platform has a proven track record of identifying molecules targeting class A & B GPCRs, including orphan receptors.
Broad discovery opportunities
We have the ability to identify a range of modulator types, including agonists, antagonists, inverse agonists, and allosteric modulators.
ConfoGen™ for antibody discovery
Without the need for protein purification, we are able to create highly immunogenic antigens that reveal the pharmacologically relevant GPCR epitope during immunization of animals. This enables the identification of a range of modulator types, particularly antibody agonists, but also antagonists, inverse agonists, and allosteric modulators.
ConfoSensor® for screening
Exquisitely sensitive cell-based GPCR assay technology suitable for screening a variety of small molecule libraries including fragment-based libraries, as well as larger high throughput collections. The cell-based ConfoSensor® system can detect low affinity, low molecular weight fragment hits from our diverse GPCR fragment library which is not possible with traditional screening methodologies.
ConfoStructure® for hi-res structures
Our revolutionary and proprietary approach to cryo-electron microscopy to generate atomic-resolution structures of GPCR-ligand complexes even with low affinity hit molecules. The approach is particularly useful for small molecule lead optimization, in conjunction with ConfoSensor®.
Partner with us
Invest in us
